Mitigating candidiasis with acarbose by targeting Candida albicans α-glucosidase: in-silico, in-vitro and

Helma David1, Sahana Vasudevan2,3, Adline Princy Solomon4

  • 1Quorum Sensing Laboratory, Centre for Research in Infectious Diseases (CRID), School of Chemical and Biotechnology, SASTRA Deemed to be University, Thanjavur, 613401, India.

Scientific Reports
|May 24, 2024
PubMed

Insights

Acarbose effectively inhibits Candida albicans biofilms and reduces virulence by targeting alpha-glucosidase. This FDA-approved drug shows promise for treating challenging fungal infections at nanomolar concentrations.

Area of Science:

  • Medical Mycology
  • Drug Discovery
  • Antifungal Resistance

Background:

  • Biofilm-associated candidiasis is a major clinical challenge due to limited treatment efficacy.
  • Candida albicans virulence and biofilm formation are critical for pathogenesis.
  • Alpha-glucosidase is a key enzyme in mannoprotein processing and a potential antifungal target.

Purpose of the Study:

  • To identify novel therapeutic agents targeting alpha-glucosidase for Candida albicans.
  • To evaluate the efficacy of FDA-approved glycomimetics against fungal biofilms and virulence.

Main Methods:

  • Virtual screening of 114 FDA-approved carbohydrate-based drugs.
  • In vitro testing of Acarbose for biofilm inhibition, virulence reduction, and host cell interaction.
  • Transcriptomic analysis to elucidate the mechanism of action.

Main Results:

  • Acarbose, an alpha-glucosidase inhibitor, was identified as a top hit.
  • Acarbose significantly inhibited Candida albicans biofilm formation and reduced virulence at nanomolar concentrations.
  • Acarbose impaired morphological switching, adhesion, and invasion of host cells.

Conclusions:

  • Acarbose demonstrates potent anti-Candida activity by targeting alpha-glucosidase.
  • Acarbose represents a promising therapeutic candidate for biofilm-associated candidiasis.
  • Targeting alpha-glucosidase offers a novel strategy to combat drug-resistant fungal infections.